{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:08:20Z","timestamp":1790096900650,"version":"4.0.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104795","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:42:28Z","timestamp":1788478948000},"page":"104795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["AI-augmented evidence as the next core competence in rare disease drug development: from snapshots to 360-degree movies"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6424-9533","authenticated-orcid":false,"given":"Ning","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104795_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1520467","article-title":"Quantifying hope: an EU perspective of rare disease therapeutic space and market dynamics","volume":"13","author":"Cacoub","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.drudis.2026.104795_b0010","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13023-018-0926-z","article-title":"Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties","volume":"13","author":"Pontes","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104795_b0015","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40273-025-01538-4","article-title":"HTA evidence in rare diseases: just rare or also special?","volume":"43","author":"Basu","year":"2025","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.drudis.2026.104795_b0020","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40271-020-00493-w","article-title":"The use of patient-reported outcome measures in rare diseases and implications for health technology assessment","volume":"14","author":"Whittal","year":"2021","journal-title":"Patient"},{"key":"10.1016\/j.drudis.2026.104795_b0025","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1038\/s41467-023-38125-0","article-title":"Cross-modal autoencoder framework learns holistic representations of cardiovascular state","volume":"14","author":"Radhakrishnan","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104795_b0030","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/psp4.70081","article-title":"Integrated modeling of digital-motor and clinician-reported outcomes using item response theory: towards powerful trials for rare neurological diseases","volume":"14","author":"Hamdan","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.drudis.2026.104795_b0035","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.neuroimage.2012.01.062","article-title":"An event-based model for disease progression and its application in familial Alzheimer\u2019s disease and Huntington\u2019s disease","volume":"60","author":"Fonteijn","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.drudis.2026.104795_b0040","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1038\/s41467-018-05892-0","article-title":"Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with subtype and stage inference","volume":"9","author":"Young","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104795_b0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40035-023-00389-3","article-title":"Novel data-driven subtypes and stages of brain atrophy in the ALS-FTD spectrum","volume":"12","author":"Shen","year":"2023","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.drudis.2026.104795_b0050","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/acn3.558","article-title":"An image-based model of brain volume biomarker changes in Huntington\u2019s disease","volume":"5","author":"Wijeratne","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.drudis.2026.104795_b0055","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/0962280217737566","article-title":"Alzheimer\u2019s Disease Neuroimaging Initiative. Bayesian latent time joint mixed effect models for multicohort longitudinal data","volume":"28","author":"Li","year":"2019","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.drudis.2026.104795_b0060","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1164\/rccm.201908-1600OC","article-title":"Disease progression modeling in chronic obstructive pulmonary disease","volume":"201","author":"Young","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.drudis.2026.104795_b0065","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.251386","article-title":"Identification of biological subtypes of Friedreich ataxia with structural MRI-based machine learning","volume":"318","author":"Pontillo","year":"2026","journal-title":"Radiology"},{"key":"10.1016\/j.drudis.2026.104795_b0070","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.cell.2019.01.006","article-title":"Optimal-transport analysis of single-cell gene expression identifies developmental trajectories in reprogramming","volume":"176","author":"Schiebinger","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104795_b0075","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s43586-024-00334-2","article-title":"Optimal transport for single-cell and spatial omics","volume":"4","author":"Bunne","year":"2024","journal-title":"Nat Rev Methods Primers"},{"key":"10.1016\/j.drudis.2026.104795_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007828","article-title":"Predicting cell lineages using autoencoders and optimal transport","volume":"16","author":"Yang","year":"2020","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.drudis.2026.104795_b0085","doi-asserted-by":"crossref","first-page":"E2467","DOI":"10.1073\/pnas.1714723115","article-title":"Fundamental limits on dynamic inference from single-cell snapshots","volume":"115","author":"Weinreb","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104795_b0090","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/sim.9949","article-title":"Modeling the multi-state natural history of rare diseases with heterogeneous individual patient data: a simulation study","volume":"43","author":"Broomfield","year":"2024","journal-title":"Stat Med"},{"key":"10.1016\/j.drudis.2026.104795_b0095","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1214\/23-AAP1969","article-title":"Toward a mathematical theory of trajectory inference","volume":"34","author":"Lavenant","year":"2024","journal-title":"Ann Appl Probab"},{"key":"10.1016\/j.drudis.2026.104795_b0100","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/epi.17855","article-title":"Natural history of rare diseases using natural language processing of narrative unstructured electronic health records: the example of Dravet syndrome","volume":"65","author":"Lo Barco","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.drudis.2026.104795_b0105","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41746-025-02004-3","article-title":"Large language models forecast patient health trajectories enabling digital twins","volume":"8","author":"Makarov","year":"2025","journal-title":"Npj Digit Med"},{"key":"10.1016\/j.drudis.2026.104795_b0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-biodatasci-110723-024625","article-title":"Graph AI in medicine","volume":"7","author":"Johnson","year":"2024","journal-title":"Annu Rev Biomed Data Sci"},{"key":"10.1016\/j.drudis.2026.104795_b0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.drudis.2026.104795_b0120","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.tig.2025.05.003","article-title":"The rare-to-common disease journey: a winding road to new therapies","volume":"41","author":"Reinholdt","year":"2025","journal-title":"Trends Genet"},{"key":"10.1016\/j.drudis.2026.104795_b0125","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.2745","article-title":"Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene","volume":"45","author":"Sosnay","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.drudis.2026.104795_b0130","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-023-02211-z","article-title":"Genetic association analysis of 77,539 genomes reveals rare disease etiologies","volume":"29","author":"Greene","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104795_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.920390","article-title":"Incomplete penetrance and variable expressivity: from clinical studies to population cohorts","volume":"13","author":"Kingdom","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.drudis.2026.104795_b0140","unstructured":"ClinicalTrials.gov. A study of VRG50635 in participants with amyotrophic lateral sclerosis. NCT06215755. Terminated December 2025."},{"key":"10.1016\/j.drudis.2026.104795_b0145","doi-asserted-by":"crossref","first-page":"20088","DOI":"10.1038\/s41598-026-48100-6","article-title":"Speech-based digital endpoints track ALS progression and align with standard clinical outcomes: evidence from the VRG50635 trial","volume":"16","author":"Neumann","year":"2026","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104795_b0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13023-026-04341-2","article-title":"European Reference Networks\u2014a flagship activity of the EU in the field of rare and complex diseases: from 2017 to 2025","volume":"21","author":"Graessner","year":"2026","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104795_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.832063","article-title":"Rare disease registries are key to evidence-based personalized medicine: highlighting the European experience","volume":"13","author":"K\u00f6lker","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.drudis.2026.104795_b0160","unstructured":"Official Journal of the European Union. Regulation (EU) 2025\/327 of the European Parliament and of the Council on the European Health Data Space. Accessed 31 July 2026. https:\/\/eur-lex.europa.eu\/eli\/reg\/2025\/327\/oj; 2025."},{"key":"10.1016\/j.drudis.2026.104795_b0165","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s13023-022-02558-5","article-title":"Towards FAIRification of sensitive and fragmented rare disease patient data: challenges and solutions in European reference network registries","volume":"17","author":"dos Santos Vieira","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104795_b0170","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1214766","article-title":"Challenges in mapping European rare disease databases, relevant for ML-based screening technologies in terms of organizational, FAIR and legal principles: scoping review","volume":"11","author":"Raycheva","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.drudis.2026.104795_b0175","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1017\/S026646232400062X","article-title":"Results of health technology assessments of orphan drugs in Germany\u2014lack of added benefit, evidence gaps, and persisting unmet medical needs","volume":"40","author":"Kranz","year":"2024","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.drudis.2026.104795_b0180","article-title":"Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer\u2019s disease","volume":"11","author":"Wang","year":"2025","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.drudis.2026.104795_b0185","unstructured":"European Medicines Agency. Qualification opinion on Prognostic Covariate Adjustment (PROCOVA). EMA\/SA\/0000059571. Accessed 31 July 2026. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/qualification-opinion-prognostic-covariate-adjustment-procovatm_en.pdf; 2022."},{"key":"10.1016\/j.drudis.2026.104795_b0190","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41746-020-0301-z","article-title":"Deep representation learning of electronic health records to unlock patient stratification at scale","volume":"3","author":"Landi","year":"2020","journal-title":"Npj Digit Med"},{"key":"10.1016\/j.drudis.2026.104795_b0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jamia\/ocaf134","article-title":"Transport-based transfer learning on electronic health records: application to detection of treatment disparities","volume":"33","author":"Li","year":"2026","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.drudis.2026.104795_b0200","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cpdd.1607","article-title":"Model-informed drug development in early-phase development: navigating complexity with quantitative clarity","volume":"14","author":"Issa","year":"2025","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.drudis.2026.104795_b0205","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1186\/s12916-025-04405-3","article-title":"Exploring synthetic controls in rare diseases with a proof of concept in spinal cord injury","volume":"23","author":"Lukas","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.drudis.2026.104795_b0210","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH harmonised tripartite guideline E10: choice of control group and related issues in clinical trials. Step 4 version, 20 July 2000. Accessed 31 July 2026. https:\/\/database.ich.org\/sites\/default\/files\/E10_Guideline.pdf."},{"key":"10.1016\/j.drudis.2026.104795_b0215","unstructured":"US Food and Drug Administration. Considerations for the design and conduct of externally controlled trials for drug and biological products: guidance for industry. Draft guidance. February 2023. Docket No. FDA-2022-D-2983. Accessed 31 July 2026. https:\/\/www.fda.gov\/media\/164960\/download."},{"key":"10.1016\/j.drudis.2026.104795_b0220","unstructured":"European Medicines Agency. Concept paper on the development of a reflection paper on the use of external controls for evidence generation in regulatory decision-making. EMA\/125200\/2026. Adopted by CHMP 21 May 2026. Accessed 31 July 2026. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/concept-paper-development-reflection-paper-use-external-controls-evidence-generation-regulatory-decision-making_en.pdf."},{"key":"10.1016\/j.drudis.2026.104795_b0225","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s43441-021-00302-y","article-title":"The use of external controls in FDA regulatory decision making","volume":"55","author":"Jahanshahi","year":"2021","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.drudis.2026.104795_b0230","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/s41416-025-03155-6","article-title":"Acceptance of external control arms by HTA agencies: a review of oncology submissions in France, England, Germany and Norway from 2021 to 2023","volume":"133","author":"Monnereau","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2026.104795_b0235","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.drudis.2026.104795_b0240","unstructured":"FDA-EMA. Joint 10 Guiding Principles of Good AI Practice in Drug Development. January 2026. Accessed 19 March 2026. https:\/\/www.fda.gov\/about-fda\/artificial-intelligence-drug-development\/guiding-principles-good-ai-practice-drug-development."},{"key":"10.1016\/j.drudis.2026.104795_b0245","unstructured":"FDA. Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products: draft guidance. January 2025. Accessed 19 March 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological."},{"key":"10.1016\/j.drudis.2026.104795_b0250","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1007\/s43441-026-00964-6","article-title":"Present and future post-marketing drug safety assessment in Japan: a PMDA perspective","volume":"60","author":"Waki","year":"2026","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.drudis.2026.104795_b0255","unstructured":"Official Journal of the European Union. Regulation (EU) 2021\/2282 of the European Parliament and of the Council on health technology assessment. 2021. Accessed 19 March 2026. https:\/\/eur-lex.europa.eu\/eli\/reg\/2021\/2282\/oj."},{"key":"10.1016\/j.drudis.2026.104795_b0260","unstructured":"Member State Coordination Group on Health Technology Assessment. Joint Clinical Assessment Summary Report of Tovorafenib. Version 1.0. Brussels: European Union; 2026. Endorsed 30 April 2026; Published 9 June 2026. Accessed 30 July 2026. https:\/\/health.ec.europa.eu\/publications\/joint-clinical-assessment-report-tovorafenib-ojemda_en."},{"key":"10.1016\/j.drudis.2026.104795_b0265","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2024-0052","article-title":"EU HTA joint clinical assessment: are patients with rare disease going to lose out?","volume":"13","author":"Castanon","year":"2024","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.drudis.2026.104795_b0270","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/jmahp14020036","article-title":"Joint clinical assessment in the EU HTA regulation\u2014would drugs supported by single-arm trials fit under evaluation?","volume":"14","author":"Kloc","year":"2026","journal-title":"J Mark Access Health Policy"},{"key":"10.1016\/j.drudis.2026.104795_b0275","unstructured":"Official Journal of the European Union. Regulation (EU) 2024\/1689 of the European Parliament and of the Council (EU AI Act). Accessed 19 March 2026. https:\/\/eur-lex.europa.eu\/eli\/reg\/2024\/1689\/oj; 2024."},{"key":"10.1016\/j.drudis.2026.104795_b0280","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41746-025-02263-0","article-title":"Challenges in applying the EU AI Act research exemptions to contemporary AI research","volume":"9","author":"Meszaros","year":"2026","journal-title":"Npj Digit Med"},{"key":"10.1016\/j.drudis.2026.104795_b0285","unstructured":"NICE. Artificial Intelligence Position Statement (ECD11). August 2024. Accessed 19 March 2026. https:\/\/www.nice.org.uk\/corporate\/ecd11."},{"key":"10.1016\/j.drudis.2026.104795_b0290","unstructured":"Member State Coordination Group on Health Technology Assessment. General principles on the use of artificial intelligence in the preparation of dossiers for Joint Clinical Assessments. Adopted 15 July 2026. Ref. hta_20260716_jca_ai-gen-principles_en. Accessed 29 July 2026. https:\/\/health.ec.europa.eu\/latest-updates\/general-principles-use-artificial-intelligence-preparation-jca-dossier-2026-07-16_en."},{"key":"10.1016\/j.drudis.2026.104795_b0295","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jval.2022.03.022","article-title":"Machine learning methods in health economics and outcomes research\u2014the PALISADE checklist: a good practices report of an ISPOR task force","volume":"25","author":"Padula","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.drudis.2026.104795_b0300","unstructured":"National Institute for Health and Care Excellence. NICE statement of intent for artificial intelligence (AI) (ECD12). Published 14 November 2024. Accessed 16 August 2026. https:\/\/www.nice.org.uk\/corporate\/ecd12."},{"key":"10.1016\/j.drudis.2026.104795_b0305","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1017\/S0266462324004720","article-title":"The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms","volume":"41","author":"Vidalis","year":"2025","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.drudis.2026.104795_b0310","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Premi\u00e8res clefs d\u2019usage de l\u2019IA g\u00e9n\u00e9rative en sant\u00e9. October 2025. https:\/\/www.has-sante.fr\/jcms\/p_3703115\/."},{"key":"10.1016\/j.drudis.2026.104795_b0315","unstructured":"Haute Autorit\u00e9 de Sant\u00e9, Commission Nationale de l\u2019Informatique et des Libert\u00e9s. Accompagner le bon usage des syst\u00e8mes d\u2019intelligence artificielle en contexte de soins. Document de travail dated 16 February 2026; Issued for public consultation 5 March\u201316 April 2026. https:\/\/www.cnil.fr\/fr\/cloturee-ia-et-sante-la-has-et-la-cnil-lancent-une-consultation-publique-sur-un-projet-de-guide."},{"key":"10.1016\/j.drudis.2026.104795_b0320","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Projet strat\u00e9gique 2025\u20132030. Saint-Denis La Plaine: Haute Autorit\u00e9 de Sant\u00e9; January 2025. Accessed 31 July 2026. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2025-02\/projet_strategique_2025_2030_has_version_web.pdf."},{"key":"10.1016\/j.drudis.2026.104795_b0325","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s40273-025-01524-w","article-title":"Challenges and criteria for single-arm trials leading to an added benefit in German health technology assessments","volume":"43","author":"Tomeczkowski","year":"2025","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.drudis.2026.104795_b0330","unstructured":"Canada\u2019s Drug Agency. Canada\u2019s Drug Agency position statement on the use of artificial intelligence in the generation and reporting of evidence. Ottawa: CDA-AMC; April 2025. Accessed 31 July 2026. https:\/\/www.cda-amc.ca\/sites\/default\/files\/MG%20Methods\/Position_Statement_AI_Renumbered.pdf."},{"key":"10.1016\/j.drudis.2026.104795_b0335","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1017\/S0266462325103395","article-title":"Advancing the use of artificial intelligence in health technology assessment activities: insights and next steps from the 2025 HTAi Global Policy Forum","volume":"42","author":"Trowman","year":"2026","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.drudis.2026.104795_b0340","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41587-024-02143-0","article-title":"A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models","volume":"43","author":"Ren","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2026.104795_b0345","unstructured":"US Food and Drug Administration. Orphan drug designations and approvals database. Orphan designation for the treatment of idiopathic pulmonary fibrosis; sponsor InSilico Medicine Hong Kong Limited; designated 1 February 2023. Listed as \u201cimidazole derivative\u201d; the USAN name rentosertib was adopted in March 2025. Accessed 30 July 2026."},{"key":"10.1016\/j.drudis.2026.104795_b0350","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1038\/s41591-025-03743-2","article-title":"A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial","volume":"31","author":"Xu","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104795_b0355","unstructured":"Insilico Medicine. Insilico initiates Phase III clinical trial for rentosertib, its AI-empowered TNIK inhibitor for idiopathic pulmonary fibrosis. Press release. 7 July 2026. ClinicalTrials.gov identifier NCT07687459."},{"key":"10.1016\/j.drudis.2026.104795_b0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pdig.0000022","article-title":"Sources of bias in artificial intelligence that perpetuate healthcare disparities\u2014a global review","volume":"1","author":"Celi","year":"2022","journal-title":"PLoS Digit Health"},{"key":"10.1016\/j.drudis.2026.104795_b0365","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s43856-025-01137-6","article-title":"Digital health technology use in clinical trials of rare diseases: a systematic review","volume":"5","author":"Mao","year":"2025","journal-title":"Commun Med"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462600200X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462600200X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:15:40Z","timestamp":1790093740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964462600200X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S135964462600200X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104795","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AI-augmented evidence as the next core competence in rare disease drug development: from snapshots to 360-degree movies","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104795"}}